Current Oncology Reports

, 20:99 | Cite as

Management of Locally Advanced and Metastatic Esophageal Cancer in the Older Population

  • Dara Bracken-Clarke
  • Abdul Rehman Farooq
  • Anne M. HorganEmail author
Geriatric Oncology (AR MacKenzie, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Geriatric Oncology


Purpose of Review

This review aims to synthesise the current literature on the management of early-stage and metastatic esophageal cancers, focusing on the older population. In particular, we aim to dissect out the elderly-specific data from the relevant trials and to discuss the issues unique to this population.

Recent Findings

While surgery is the curative modality in esophageal malignancies, the CROSS, MAGIC and FLOT trials demonstrate a clear advantage to neoadjuvant therapy (chemotherapy and chemoradiotherapy). These trials, however, included few elderly patients. There is a similar lack of elderly-specific data in the metastatic setting.


Esophageal malignancies remain highly lethal with increasing incidence with age. Despite the relative lack of elderly-specific data, the fit older population appear to similarly benefit from multimodal therapy in early-stage and palliative therapy in metastatic disease.


Cancer Oesophagus Oesophago-gastric junction Elderly Chemotherapy 


Compliance with Ethical Standards

Conflict of Interest

Dara Bracken-Clarke, Abdul Rehman Farooq, and Anne M. Horgan declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    SEER Cancer Statistics Review, 1975-2015 [Internet]. Surveillance Research Program of the NCI. 2018. Available from:
  2. 2.
    • van Putten M, de Vos-Geelen J, Nieuwenhuijzen GAP, Siersema PD, Lemmens V, Rosman C, et al. Long-term survival improvement in oesophageal cancer in the Netherlands. Eur J Cancer. 2018;94:138–47 This article reports the trends in diagnosis, treatment, histology and survival for oesophageal cancer in the Netherlands Cancer Registry in the period 1989–2014. It reports incidence, subtype, survival, age and treatment modality—thus yielding extensive demographic and therapeutic data across time. PubMedGoogle Scholar
  3. 3.
    •• van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84 This article reports the Dutch CROSS trial, assessing the efficacy of neoadjuvant chemoradiotherapy (carboplatin/paclitaxel, 41.4Gy) followed by surgery vs surgery alone for locally advanced oesophageal cancer. Although fewer older patients were included, it represents a worldwide standard-of-care for trimodality therapy in oesophageal cancer. Thus, it remains highly relevant in any treatment plan for locally advanced disease. PubMedGoogle Scholar
  4. 4.
    • Stahl M, Budach W. Definitive chemoradiotherapy. J Thorac Dis. 2017;9(Suppl 8):S792–S8 This review discusses the various regimens (both chemotherapy and radiotherapy) used for radical treatment of oesophageal cancer. There is less focus on age however side effect data and long-term remission rate with chemoradiotherapy +/- surgery—which may be a very important factor in the older population. PubMedPubMedCentralGoogle Scholar
  5. 5.
    Shao MS, Wong AT, Schwartz D, Weiner JP, Schreiber D. Definitive or preoperative chemoradiation therapy for esophageal cancer: patterns of care and survival outcomes. Ann Thorac Surg. 2016;101(6):2148–54.PubMedGoogle Scholar
  6. 6.
    Lester SC, Lin SH, Chuong M, Bhooshan N, Liao Z, Arnett AL, et al. A multi-institutional analysis of trimodality therapy for esophageal cancer in elderly patients. Int J Radiat Oncol Biol Phys. 2017;98(4):820–8.PubMedGoogle Scholar
  7. 7.
    •• Guttmann DM, Mitra N, Metz JM, Plastaras J, Feng W, Swisher-McClure S. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer. J Geriatr Oncol. 2018;9(1):40–6 This article reports a large observational cohort study of neoadjuvant chemoradiotherapy specifically in an older population. It confirms the efficacy and tolerability of trimodality therapy in the elderly, confirming previous extrapolations from the CROSS study. Thus, it offers clear evidence for this approach in the elderly and is relevant to treatment decisions in this population. PubMedGoogle Scholar
  8. 8.
    Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, et al. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: the SEER-Medicare cohort. Int J Radiat Oncol Biol Phys. 2009;74(2):482–9.PubMedGoogle Scholar
  9. 9.
    Fogh SE, Yu A, Kubicek GJ, Scott W, Mitchell E, Rosato EL, et al. Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy? Int J Radiat Oncol Biol Phys. 2011;80(5):1372–6.PubMedGoogle Scholar
  10. 10.
    Ruol A, Portale G, Castoro C, Merigliano S, Cagol M, Cavallin F, et al. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer. Ann Surg Oncol. 2007;14(11):3243–50.PubMedGoogle Scholar
  11. 11.
    Camerlo A, D'Journo XB, Ouattara M, Trousse D, Doddoli C, Thomas PA. Adenocarcinoma of the esophagus and esophagogastric junction in patients older than 70 years: results of neoadjuvant radiochemotherapy followed by transthoracic esophagectomy. J Visc Surg. 2012;149(3):e203–10.PubMedGoogle Scholar
  12. 12.
    Bernardi D, Asti E, Aiolfi A, Bonitta G, Luporini A, Bonavina L. Outcome of trimodal therapy in elderly patients with esophageal cancer: prognostic value of the Charlson Comorbidity Index. Anticancer Res. 2018;38(3):1815–20.PubMedGoogle Scholar
  13. 13.
    Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37.PubMedGoogle Scholar
  14. 14.
    Jougon JB, Ballester M, Duffy J, Dubrez J, Delaisement C, Velly JF, et al. Esophagectomy for cancer in the patient aged 70 years and older. Ann Thorac Surg. 1997;63(5):1423–7.PubMedGoogle Scholar
  15. 15.
    Honore C, Al-Azzeh A, Gilson N, Van Daele D, Polus M, Meurisse M, et al. Esophageal cancer surgery in patients older than 75: long term results. Acta Chir Belg. 2011;111(1):12–7.PubMedGoogle Scholar
  16. 16.
    Ra J, Paulson EC, Kucharczuk J, Armstrong K, Wirtalla C, Rapaport-Kelz R, et al. Postoperative mortality after esophagectomy for cancer: development of a preoperative risk prediction model. Ann Surg Oncol. 2008;15(6):1577–84.PubMedGoogle Scholar
  17. 17.
    Moskovitz AH, Rizk NP, Venkatraman E, Bains MS, Flores RM, Park BJ, et al. Mortality increases for octogenarians undergoing esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2006;82(6):2031–6 discussion 6.PubMedGoogle Scholar
  18. 18.
    Adam DJ, Craig SR, Sang CT, Cameron EW, Walker WS. Esophagectomy for carcinoma in the octogenarian. Ann Thorac Surg. 1996;61(1):190–4.PubMedGoogle Scholar
  19. 19.
    Bonavina L, Incarbone R, Saino G, Clesi P, Peracchia A. Clinical outcome and survival after esophagectomy for carcinoma in elderly patients. Dis Esophagus. 2003;16(2):90–3.PubMedGoogle Scholar
  20. 20.
    Rice DC, Correa AM, Vaporciyan AA, Sodhi N, Smythe WR, Swisher SG, et al. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005;79(2):391–7 discussion −7.PubMedGoogle Scholar
  21. 21.
    Morita M, Egashira A, Yoshida R, Ikeda K, Ohgaki K, Shibahara K, et al. Esophagectomy in patients 80 years of age and older with carcinoma of the thoracic esophagus. J Gastroenterol. 2008;43(5):345–51.PubMedGoogle Scholar
  22. 22.
    Pultrum BB, Bosch DJ, Nijsten MW, Rodgers MG, Groen H, Slaets JP, et al. Extended esophagectomy in elderly patients with esophageal cancer: minor effect of age alone in determining the postoperative course and survival. Ann Surg Oncol. 2010;17(6):1572–80.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Cijs TM, Verhoef C, Steyerberg EW, Koppert LB, Tran TC, Wijnhoven BP, et al. Outcome of esophagectomy for cancer in elderly patients. Ann Thorac Surg. 2010;90(3):900–7.PubMedGoogle Scholar
  24. 24.
    Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg. 2007;205(6):729–34.PubMedGoogle Scholar
  25. 25.
    Zhang X, Yang Y, Ye B, Sun Y, Guo X, Hua R, et al. Minimally invasive esophagectomy is a safe surgical treatment for locally advanced pathologic T3 esophageal squamous cell carcinoma. J Thorac Dis. 2017;9(9):2982–91.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379(9829):1887–92.PubMedGoogle Scholar
  27. 27.
    Nagpal K, Ahmed K, Vats A, Yakoub D, James D, Ashrafian H, et al. Is minimally invasive surgery beneficial in the management of esophageal cancer? A meta-analysis. Surg Endosc. 2010;24(7):1621–9.PubMedGoogle Scholar
  28. 28.
    Dantoc M, Cox MR, Eslick GD. Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg. 2012;147(8):768–76.PubMedGoogle Scholar
  29. 29.
    Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–8.PubMedGoogle Scholar
  30. 30.
    Honing J, Smit JK, Muijs CT, Burgerhof JG, de Groot JW, Paardekooper G, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol. 2014;25(3):638–43.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Tougeron D, Di Fiore F, Thureau S, Berbera N, Iwanicki-Caron I, Hamidou H, et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer. 2008;99(10):1586–92.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Anderson SE, Minsky BD, Bains M, Hummer A, Kelsen D, Ilson DH. Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer. 2007;96(12):1823–7.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Tougeron D, Hamidou H, Scotte M, Di Fiore F, Antonietti M, Paillot B, et al. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer. 2010;10:510.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Munch S, Heinrich C, Habermehl D, Oechsner M, Combs SE, Duma MN. Primary radio(chemo)therapy for esophageal cancer in elderly patients: are efficiency and toxicity comparable with younger patients? Eur J Med Res. 2017;22(1):24.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Lu X, Wu H, Wang J, Xu J. Short- and long-term outcomes of definitive chemoradiotherapy in patients with esophageal carcinoma aged >/=75 years. Mol Clin Oncol. 2014;2(2):297–301.PubMedGoogle Scholar
  36. 36.
    Xu C, Xi M, Moreno A, Shiraishi Y, Hobbs BP, Huang M, et al. Definitive chemoradiation therapy for esophageal cancer in the elderly: clinical outcomes for patients exceeding 80 years old. Int J Radiat Oncol Biol Phys. 2017;98(4):811–9.PubMedGoogle Scholar
  37. 37.
    Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7.PubMedGoogle Scholar
  38. 38.
    Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.PubMedGoogle Scholar
  39. 39.
    Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol. 2016;34(23):2736–42.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547–53.PubMedGoogle Scholar
  41. 41.
    Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–42.PubMedGoogle Scholar
  42. 42.
    Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20(8):1996–2004.PubMedGoogle Scholar
  43. 43.
    Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261–7.PubMedGoogle Scholar
  44. 44.
    Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–9.PubMedGoogle Scholar
  45. 45.
    Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.PubMedGoogle Scholar
  46. 46.
    Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33(8):1216–20.PubMedGoogle Scholar
  47. 47.
    Kok TC, van der Gaast A, Splinter TA. 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. Ann Oncol. 1996;7(5):533–4.PubMedGoogle Scholar
  48. 48.
    Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 2007;18(5):898–902.PubMedGoogle Scholar
  49. 49.
    Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955–9.PubMedGoogle Scholar
  50. 50.
    Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, et al. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol. 2010;36(3):601–6.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Berger AK, Zschaebitz S, Komander C, Jager D, Haag GM. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: a retrospective cohort study at the National Center for Tumor Diseases, Heidelberg. World J Gastroenterol. 2015;21(16):4911–8.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991–7.PubMedGoogle Scholar
  53. 53.
    Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer. 2013;49(4):835–42.PubMedGoogle Scholar
  54. 54.
    Hofheinz RD, Al-Batran SE, Ridwelski K, Gorg C, Wehle K, Birth M, et al. Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany. Onkologie. 2010;33(10):512–8.PubMedGoogle Scholar
  55. 55.
    Morris H. Dysphagia in the elderly - a management challenge for nurses. Br J Nurs. 2006;15(10):558–62.PubMedGoogle Scholar
  56. 56.
    Bloem BR, Lagaay AM, van Beek W, Haan J, Roos RA, Wintzen AR. Prevalence of subjective dysphagia in community residents aged over 87. BMJ. 1990;300(6726):721–2.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Diamantis G, Scarpa M, Bocus P, Realdon S, Castoro C, Ancona E, et al. Quality of life in patients with esophageal stenting for the palliation of malignant dysphagia. World J Gastroenterol: WJG. 2011;17(2):144–50.PubMedGoogle Scholar
  58. 58.
    Amdal CD, Jacobsen AB, Guren MG, Bjordal K. Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review. Acta Oncol. 2013;52(4):679–90.PubMedGoogle Scholar
  59. 59.
    Kassam Z, Wong RK, Ringash J, Ung Y, Kamra J, DeBoer G, et al. A phase I/II study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus. Clin Oncol (R Coll Radiol). 2008;20(1):53–60.Google Scholar
  60. 60.
    Hayter CR, Huff-Winters C, Paszat L, Youssef YM, Shelley WE, Schulze K. A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer. Radiother Oncol. 2000;56(3):329–33.PubMedGoogle Scholar
  61. 61.
    Fuccio L, Mandolesi D, Farioli A, Hassan C, Frazzoni L, Guido A, et al. Brachytherapy for the palliation of dysphagia owing to esophageal cancer: a systematic review and meta-analysis of prospective studies. Radiother Oncol. 2017;122(3):332–9.PubMedGoogle Scholar
  62. 62.
    Singh P, Singh A, Singh A, Sharma G, Bhatia PK, Grover AS. Long term outcome in patients with esophageal stenting for cancer esophagus - our experience at a Rural Hospital of Punjab, India. J Clin Diagn Res. 2016;10(12):PC06–PC9.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Kim KY, Tsauo J, Song H-Y, Kim PH, Park J-H. Self-expandable metallic stent placement for the palliation of esophageal cancer. J Korean Med Sci. 2017;32(7):1062–71.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Sharma P, Kozarek R. Role of esophageal stents in benign and malignant diseases. Am J Gastroenterol. 2010;105(2):258–73 quiz 74.PubMedGoogle Scholar
  65. 65.
    Mocanu A. Endoscopic palliation of advanced esophageal cancer. J Med Life. 2015;8:193–201.Google Scholar
  66. 66.
    Yoon HY, Cheon YK, Choi HJ, Shim CS. Role of photodynamic therapy in the palliation of obstructing esophageal cancer. Korean J Intern Med. 2012;27(3):278–84.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Luketich JD, Christie NA, Buenaventura PO, Weigel TL, Keenan RJ, Nguyen NT. Endoscopic photodynamic therapy for obstructing esophageal cancer: 77 cases over a 2-year period. Surg Endosc. 2000;14(7):653–7.PubMedGoogle Scholar
  68. 68.
    Ye X-J, Ji Y-B, Ma B-W, Huang D-D, Chen W-Z, Pan Z-Y, et al. Comparison of three common nutritional screening tools with the new European Society for Clinical Nutrition and Metabolism (ESPEN) criteria for malnutrition among patients with geriatric gastrointestinal cancer: a prospective study in China. BMJ Open. 2018;8(4):e019750.PubMedPubMedCentralGoogle Scholar
  69. 69.
    • Pressoir M, Desné S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010;102:966 This article reports the incidence of malnutrition in an undifferentiated French oncology population. It is relevant both to the underlying incidence of malnutrition and to its impact on survival. PubMedPubMedCentralGoogle Scholar
  70. 70.
    • Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord. 2017;16:21 This article reports overall sarcopaenia rates worldwide in the older population—which continue to rise with advancing age. This is of particular relevance to oesophageal cancer given the significantly increased complications (especially surgical complications) associated with sarcopaenia. PubMedPubMedCentralGoogle Scholar
  71. 71.
    Makary MA, Segev DL, Pronovost PJ, Syin D, Bandeen-Roche K, Patel P, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg. 2010;210(6):901–8.PubMedGoogle Scholar
  72. 72.
    Sundermann S, Dademasch A, Praetorius J, Kempfert J, Dewey T, Falk V, et al. Comprehensive assessment of frailty for elderly high-risk patients undergoing cardiac surgery. Eur J Cardiothorac Surg. 2011;39(1):33–7.PubMedGoogle Scholar
  73. 73.
    Afilalo J, Eisenberg MJ, Morin JF, Bergman H, Monette J, Noiseux N, et al. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. J Am Coll Cardiol. 2010;56(20):1668–76.PubMedGoogle Scholar
  74. 74.
    Rostoft S, Audisio RA. Recent advances in cancer surgery in older patients. F1000Research. 2017;6:1242.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty states among community-living older persons. Arch Intern Med. 2006;166(4):418–23.PubMedGoogle Scholar
  76. 76.
    Forster A, Lambley R, Young JB. Is physical rehabilitation for older people in long-term care effective? Findings from a systematic review. Age Ageing. 2010;39(2):169–75.PubMedGoogle Scholar
  77. 77.
    Partridge JS, Harari D, Martin FC, Dhesi JK. The impact of pre-operative comprehensive geriatric assessment on postoperative outcomes in older patients undergoing scheduled surgery: a systematic review. Anaesthesia. 2014;69(Suppl 1):8–16.PubMedGoogle Scholar
  78. 78.
    Partridge J, Sbai M, Dhesi J. Proactive care of older people undergoing surgery. Aging Clin Exp Res. 2018;30(3):253–7.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Partridge JS, Harari D, Martin FC, Peacock JL, Bell R, Mohammed A, et al. Randomized clinical trial of comprehensive geriatric assessment and optimization in vascular surgery. Br J Surg. 2017;104(6):679–87.PubMedGoogle Scholar
  80. 80.
    McIsaac DI, Huang A, Wong CA, Wijeysundera DN, Bryson GL, van Walraven C. Effect of preoperative geriatric evaluation on outcomes after elective surgery: a population-based study. J Am Geriatr Soc. 2017;65(12):2665–72.PubMedGoogle Scholar
  81. 81.
    Le Roy B, Pereira B, Bouteloup C, Costes F, Richard R, Selvy M, et al. Effect of prehabilitation in gastro-oesophageal adenocarcinoma: study protocol of a multicentric, randomised, control trial-the PREHAB study. BMJ Open. 2016;6(12):e012876.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Harari D, Hopper A, Dhesi J, Babic-Illman G, Lockwood L, Martin F. Proactive care of older people undergoing surgery ('POPS'): designing, embedding, evaluating and funding a comprehensive geriatric assessment service for older elective surgical patients. Age Ageing. 2007;36(2):190–6.PubMedGoogle Scholar
  83. 83.
    Mohile SG, Xian Y, Dale W, Fisher SG, Rodin M, Morrow GR, et al. Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J Natl Cancer Inst. 2009;101(17):1206–15.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Guerard EJ, Deal AM, Williams GR, Jolly TA, Nyrop KA, Muss HB. Falls in older adults with cancer: evaluation by oncology providers. J Oncol Pract. 2015;11(6):470–4.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Jolly TA, Deal AM, Nyrop KA, Williams GR, Pergolotti M, Wood WA, et al. Geriatric assessment-identified deficits in older cancer patients with normal performance status. Oncologist. 2015;20(4):379–85.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Puts MT, Santos B, Hardt J, Monette J, Girre V, Atenafu EG, et al. An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol. 2014;25(2):307–15.PubMedGoogle Scholar
  88. 88.
    Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86.Google Scholar
  89. 89.
    Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Dara Bracken-Clarke
    • 1
  • Abdul Rehman Farooq
    • 1
  • Anne M. Horgan
    • 1
    Email author
  1. 1.Medical Oncology DepartmentUniversity Hospital WaterfordWaterfordIreland

Personalised recommendations